Project Grant K99HL177326
Award Date
1/2/25
Completion Date
12/31/26
Dollars Obligated
$127K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
This $844,386 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, supports the "Integrative Genomics of Childhood Interstitial Lung Disease" research project at Boston Children's Hospital. The key objectives are to: Define patient clusters with similar molecular profiles from 300 childhood interstitial and diffuse lung disease (CHILD) lung biopsy samples, develop a CHILD molecular...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $167,940 to The Children's Hospital Corporation (doing business as Boston Children's Hospital) to support research focused on understanding the role of smooth muscle cells in vascular remodeling related to flow-induced pulmonary hypertension. The key objectives of this 5-year research project are to: 1) develop a novel mouse model that...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $833,681 to The Children's Hospital Corporation (Boston Children's Hospital) to conduct research aimed at understanding the role of endothelial epsins in regulating myocardial ischemia and heart regeneration. The research seeks to uncover novel molecular mechanisms and identify new therapeutic targets to improve treatment of ischemic...
The federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $834,531 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct research on the effects of IL-1 beta inhibition on vascular inflammation in individuals with clonal hematopoiesis of indeterminate potential (CHIP), an emerging risk factor for atherosclerotic cardiovascular disease (ASCVD)....
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $2,654,903 to The Children's Hospital Corporation (doing business as Boston Children's Hospital) to develop innovative gene therapy technologies for the in vivo and ex vivo delivery of genetic payloads to hematopoietic stem cells. The objectives are to: (1) develop integrating vectors to deliver a curative transgene for X-linked...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $657,308 to The Children's Hospital of Philadelphia (CHOP) to conduct research on the CXCL12 signaling axis and its role in pulmonary arterial heterogeneity, development, and disease. The key objectives of this 12-month project are to: 1) define the spatiotemporal role of CXCL12 signaling in pulmonary vascular development, 2)...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,127,798.00 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct research on the role of macrophages in preserving cardiovascular health and their contributions to cardiovascular disease (CVD). The research aims to identify harmful macrophage subsets and their functions, and to define...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $483,852 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), for the development of a platform technology to measure the kinetics and equilibrium concentration of sickle hemoglobin polymerization in single red blood cells. This new platform will enable the optimization of treatment discovery, patient response...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $827,665 to the New York Genome Center, Inc. (Nygc) to develop scalable methods for identifying causal genetic variants, relevant cell types, and target genes associated with cardiovascular disease (CVD). The key products and services to be delivered include: Performing colocalization of CVD and blood cell trait genome-wide association...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,123,357 to Childrens Hospital Medical Center in Cincinnati, Ohio. The research project aims to define the physiology of blood cell production in the bone marrow tissue during homeostasis, inflammation, and regeneration. Key objectives include: Dissecting the function of specialized microenvironments that serve as niches for...